Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

NCT05393284 is registered in ClinicalTrials.gov with Valo Health, Inc. as lead sponsor.

NCT NCT05393284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05393284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
Lead sponsor
Valo Health, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
August 16, 2022
Completion date
August 31, 2024
Enrollment
114 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

non-proliferative diabetic retinopathy, proliferative diabetic retinopathy